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Abstract
Background: The reduction of blood pressure alone does not eliminate the increased risk of
arterial hypertension. Whilst concomitant metabolic risk factors have been shown to be
responsible, the available pharmacotherapy has differential effects on these metabolic risk factors.
For example, diuretics and betablockers worsen glucose metabolism, hence the starting point of
the current subanalysis of the CHILI (Candesartan in patients with HIgher cardiovascuLar rIsk)
study was the assumption that an angiotensin receptor blocker may counterbalance the metabolic
effects of a low dose diuretic in patients with several metabolic risk factors.
Methods:  The present study was performed as a non-interventional observational study in
Germany. Patients with previously uncontrolled hypertension with at least one further risk factor
in which physicians deemed a treatment with 16 mg Candesartan/12.5 mg HCTZ to be necessary
were included. The risk factors were calculated in patient subgroups with diabetes, the metabolic
syndrome (MetSyn) and neither condition (control). The risk of cardiovascular mortality within the
next 10 years was calculated using the SCORE algorithm of the ESC.
Results: Between August 2006 and February 2007 a total of 3,787 patients were included into the
non-interventional trial. Patients were 62.2 ± 11.3 years old, 48.1% were female, 97.5% had at least
one additional risk factor. Blood pressure was reduced by -27.2/-13.4 mmHg with only minor non
significant variations between patient groups. Waist circumference was reduced (P < 0.0001) and
HDL-C elevated (P < 0.05) in every subgroup except the control subgroup. Fasting blood glucose
was reduced by -5.6 ± 21.6% (P < 0.0001 vs. baseline and vs. control) as well as triglycerides (-4.9
± 29.4%; P < 0.0001 vs. baseline and vs. control). The SCORE value was reduced substantially (-8.7,
-3.2 and -2.7% in patients with diabetes, the metabolic syndrome or neither).
Conclusion: The present study demonstrates that a 16 mg candesartan/12.5 mg HCTZ based
treatment results in a pronounced blood pressure reduction and was associated with a favourable
change in metabolic risk factors such as HDL cholesterol, triglycerides and blood glucose. These
data indicate that metabolic effects observed in clinical trials like ALPINE, SCOPE or CHARM can
also be observed in an unselected patient population in primary care.
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Background
Arterial hypertension is one of the most prevalent risk fac-
tors for cardiovascular disease [1-3] and an important
cause of death worldwide [4]. The relationship between
blood pressure and cardiovascular risk is almost linear in
patients without end organ damage [5,6] and an arbitrary
threshold of 140/90 mmHg has been defined to simplify
diagnosis and treatment approaches in daily practice [7].
Lifestyle interventions have been proposed to lower blood
pressure and cardiovascular risk [8], but they often fail to
be long-term solutions. Therefore a number of anti-hyper-
tensive drugs have been developed, giving clinicians many
options. Whilst lowering BP is a mainstay of cardiovascu-
lar risk reduction, it is important to treat the other cardio-
vascular risk factors as well [9].
Hypertension is frequently found together with other
metabolic risk factors (low HDL-Cholesterol, abdominal
obesity, high triglycerides, high fasting blood glucose
etc.). The HOT study for example found that each of the
risk factors considered was an important cause of residual
risk, despite good blood pressure control [9]. It therefore
seems to be of principal importance to address other cor-
rectable risk factors and to be particularly conscious about
the metabolic effects of antihypertensive drugs even in
patients being treated to goal (120/80 mmHg).
In a recent meta-analysis Elliott and colleagues [10]
showed that increased blood sugar values and the subse-
quent development of diabetes occur more often in
patients receiving diuretics and betablockers instead of
angiotensin receptor blockers (ARBs) and angiotensin
converting enzyme (ACE) inhibitors. Furthermore it was
recently demonstrated that patients on betablockade have
more difficulties to reduce abdominal obesity and addi-
tional metabolic risk factors than those patients on a com-
bination of renin-angiotensin system (RAS) blocking
agents and Calcium Channel Blockers (CCBs) [11]. Of
note, the ARB, candesartan reduced the number of
patients developing diabetes in the CHARM [12], SCOPE
[13] and ALPINE: [14] trial. When candesartan was
administered to a group of hypertensive subjects it caused
a reduction in C-reactive protein and an increase in adi-
ponectin and markers of insulin sensitivity; as measured
by QUICKI (Quantitative Insulin-Sensitivity Check Index)
index [15].
Of particular interest within this context is a combination
of candesartan with a low dose diuretic (12.5 mg hydro-
chlorothiazide, HCTZ) and to test whether the properties
of both agents combine to create a beneficial outcome for
patients. It was therefore the aim of the present analysis of
the non interventional CHILI (Candesartan in patients
with HIgher cardiovascuLar rIsk) study to investigate the
influence of candesartan in fixed combination with HCTZ
on a number of metabolic parameters and cardiovascular
risk factors in more detail. The study was conducted in a
primary care setting in order to acquire the broadest pos-
sible spectrum of patients in clinical practice. Three core
questions were to be answered: 1) reduction in blood
pressure; 2) reduction of cardiovascular risk factors like
fasting glucose, waist circumference, triglycerides, HDL-
Cholesterol after 8 week treatment and differential effects
in patients with diabetes, the metabolic syndrome and
neither disease state; 3) change in the absolute 10 year risk
of cardiovascular morbidity (using the SCORE method)
and the contribution of a) blood pressure and b) meta-
bolic effects to this effect.
Methods
The present non-interventional study was conducted
between August 2006 and February 2007 with the help of
893 primary care physicians all over Germany. Therefore
a sample of general practitioners, internists, cardiologists
and practical physicians was drawn from all segments of
the Institute for Medical Statistics (IMS, Frankfurt, Ger-
many). The study was duly notified according to local
laws and regulations (§ 67 (6) Arzneimittelgesetz, AMG)
to the higher authorities (Bundesinstitut für Arzneimittel
und Medizinprodukte, BfArM) and the federal panel doc-
tors' association (Kassenärztliche Bundesvereinigung,
KBV). Approval was obtained by the Technical University
Dresden ethical committee. Due to regulations for this
kind of study no patient informed consent had to be
obtained. Methods of this study have been published pre-
viously [16].
Patients
Patients were at least 18 years old, had essential arterial
hypertension with blood pressure values beyond 140/90
mmHg (> 130/85 mmHg in diabetic patients) and previ-
ous antihypertensive therapy of at least 8 weeks duration
had proven unsuccessful. In addition to this one of the
following risk factors had to be present: Diabetes mellitus,
dyslipidemia, abdominal obesity, hs-CRP ≥ 2 mg/l or con-
firmation of microalbuminaria (MAU). Patients who ful-
filled these criteria and who's treating physician deemed a
treatment with 16 mg Candesartan/12.5 mg HCTZ to be
necessary were documented.
Metabolic Syndrome definition
The AHA/NHLBI 2004 definition was used to determine
the presence of the metabolic syndrome [17]. It requests
that 3 out of the following 5 criteria are met: 1) waist cir-
cumference > 102 cm in men and > 88 cm in women; 2)
blood pressure readings ≥ 130 mmHg systolic or ≥ 85
mmHg diastolic; 3) fasting glucose ≥ 5.6 mmol/L (≥ 100
mg/dL) or known diabetes mellitus; 4) triglycerides ≥ 1.7
mmol/l (≥ 150 mg/dL); 5) HDL-Cholesterol < 1.0 mmol/BMC Cardiovascular Disorders 2008, 8:30 http://www.biomedcentral.com/1471-2261/8/30
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L (40 mg/dL) in men, and < 1.3 mmol/L (50 mg/dL) in
women.
Calculation of the SCORE value
The following parameters were used for the calculation of
the score [18]: sex, age, HDL-C, total cholesterol (either
indicated or calculated by the Friedewald formula), systo-
lic BP and smoking status. In the presence of diabetes, the
score was increased by a factor of 2 in men and by a factor
of 4 in women. Calculations were done without replace-
ment of missing values. To calculate the blood pressure
risk reduction attributable to diabetes, the baseline
SCORE risk was modified by replacing the blood pressure
baseline value by the 8 week follow-up value but keeping
the baseline values for metabolic risk factors. To calculate
the risk attributable to metabolic changes, baseline
SCORE risk was modified by replacing the baseline values
of metabolic parameters by the 8 week values but keeping
the baseline blood pressure within the model.
Study conduct
Physicians were asked to document at least 3 patients with
arterial hypertension and concomitant cardiovascular risk
factors. The observational period was 8 weeks and
patients had a voluntary additional visit at 4 weeks and
the case report forms were retrieved by the CRO Christine
Franzen Consulting, (Stolberg, Germany) and screened
routinely for plausibility and completeness. Source data
verification was however not performed. Confidentiality:
Patient data were recorded anonymously (age and gender
only). Electronic data processing was conducted in
accordance with local laws and regulations and the partic-
ipating GPs received remuneration for the documentation
of each patient which was in accordance with the
"Gebührenordnung für Ärzte" (GOÄ).
Statistical Analyses
Regarding safety, the trial was adequately sized (n =
3,787) to identify rare AEs, i.e. those that may not have
been detected in previous clinical studies, (incidence 1:
1,000) with a probability of > 99%. These data have been
published previously [16]. The statistical analysis was per-
formed descriptively and was interpreted in an explorative
way. Comparisons were made for a number of variables
and analyzed using descriptive statistics. The number of
patients is given for each value and differences were calcu-
lated in patients with values at baseline and follow-up
(per protocol). The analysis of data was performed with
ACCESS 2003 and Winstat for Microsoft Excel. Tests
applied are indicated in the legends of tables and figures.
Results
3,787 patients were included into the present study. The
patients had a mean age of 62.2 ± 11.3 years, 48.1% were
female and BMI was 29.5 ± 4.7 kg/m2. 97.5% had at least
one cardiovascular risk factor, 29.8% existing cardiovascu-
lar disease. 13.0% of patients had angina pectoris, 12.5%
heart failure, 8.4% myocardial infarction, 6.2% kidney
failure and 4.9% previous stroke.
Cardiovascular risk factors over time
The risk factors making up the metabolic syndrome were
elevated throughout all patient subgroups (metabolic syn-
drome, with diabetes mellitus and neither condition)
with hypertension (inclusion criterion), dyslipidemia
(78.2%) and abdominal obesity (65.4%) being the most
frequent. Tables 1, 2 and 3 display the course of these risk
factors throughout the study in patients with the meta-
bolic syndrome, with diabetes mellitus and neither condi-
tion. Blood pressure was significantly reduced in all
patients (-27.2/-13.4 p < 0.0001) and there was no signif-
icant difference between the extent of blood pressure low-
ering (p = n.s.) between groups. Fasting blood glucose and
triglycerides were unchanged in patients without the met-
abolic syndrome or diabetes only (p = n.s.); every other
parameter was significantly changed versus baseline in a
positive direction.
Comparison between different patient groups
Figure 1 displays the relative change in risk factors in com-
parison between the three groups of patients. While fast-
ing plasma glucose was unchanged (p = n.s.) in patients
with neither the metabolic syndrome nor diabetes it was
gradually reduced in patients with the metabolic syn-
drome (-1.6 ± 12.1%; p < 0.0001 vs. baseline) and
strongly reduced in patients with diabetes (-5.6 ± 21.6%;
p < 0.0001 vs. baseline). This corresponded to a mean
absolute reduction of -2.5 ± 13.1 and -10.8 ± 30.1 mg/dL
respectively. Triglycerides were similarly unchanged in the
control group while they were reduced in MetSyn (-4.1 ±
43.9%; p < 0.0001 vs. baseline) and Diabetes (-4.9 ±
29.4%; p < 0.0001). Mean absolute values were -19.1 ±
61.0 and -23.3 ± 76.2 mg/dl respectively.
Absolute cardiovascular risk in comparison to normal age 
matched controls
Finally absolute cardiovascular risk was calculated accord-
ing to the SCORE method. The baseline risk differed sub-
stantially in the three patient subgroups (Diabetes 19.8 >
MetSyn 7.4 > Neither 6.4%) as did the absolute risk reduc-
tion (Diabetes -8.7 > MetSyn -3.2 > Neither -2.7%). For
details see table 4. The SCORE value was also calculated
assuming that a) blood pressure was unchanged (risk
reduction of -2.6, -2.9 and -7.6% in patients with neither,
MetSyn or diabetes respectively) and b) that all other risk
factors were unchanged (-0.4, -0.7 and -1.4) to estimate
the proportion of risk reduction from the antihyperten-
sive effect of candesartan (Table 4).BMC Cardiovascular Disorders 2008, 8:30 http://www.biomedcentral.com/1471-2261/8/30
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Discussion
Antihypertensive drugs have been shown to have differen-
tial effects on metabolic parameters in clinical trials and
recent meta analyses [10]. Treatment with ARBs was asso-
ciated with a reduced incidence of diabetes mellitus com-
pared to placebo, diuretics and betablockers [10,19].
Consistent with this notion Law and colleagues recom-
mend a combination of a standard dose of a RAS blocking
agent with low doses of non-RAS blocking agents, as only
the RAS blocking agents had no evidence of dose related
adverse events [20]. The intention was to achieve substan-
tial reductions in blood pressure with a reduction of drug
related side effects. This approach has been well translated
into the development of fixed dose drug-drug combina-
tions. In the present non interventional study conducted
in primary care a fixed dose combination of 16 mg cande-
Table 1: Cardiovascular risk factors at baseline and follow-up in patients without the metabolic syndrome1 and diabetes mellitus2
Baseline 8 weeks difference2
Nm e a n±  S DNm e a n±  S DNm e a n±  S D
Blood pressure
systolic mmHg 354 159.8 14.7 348 133.0 10.8 341 -27.0* 14.5
diastolic mmHg 353 93.3 9.3 348 80.7 6.0 340 -12.8* 10.1
Fasting plasma glucose
mg/dL 354 85.9 11.5 205 86.8 14.5 203 1.7 15.0
Waist circumference
men cm 141 97.9 10.4 135 96.8 9.7 133 -0.8* 1.9
women cm 142 88.8 11.7 130 87.8 10.5 130 -0.6* 2.8
Triglycerides
mg/dL 351 138.0 80.6 197 137.7 57.6 195 0.3 3.86
HDL Cholesterol
men mg/dL 169 54.1 13.9 94 53.8 13.2 94 1.6 10.7
women mg/dL 183 67.4 17.3 96 66.6 17.1 95 -0.7 15.8
1 defined by the AHA/NHLBI 2004 [17]; 2 diagnosis assigned by physician; 3 difference versus baseline; statistical test applied: t-test; * p < 0.0001. 
Adjusted for age.
Table 2: Cardiovascular risk factors at baseline and follow-up in patients with the metabolic syndrome1
Baseline 8 weeks Difference2
N m e a n±  S D N m e a n±  S D N m e a n±  S D
Blood pressure
systolic mmHg 1319 160.0 13.8 1312 133.3 10.4 1289 -26.6* 14.3
diastolic mmHg 1319 94.6 8.6 1312 80.9 6.5 1289 -13.6* 9.2
Fasting plasma glucose
mg/dL 1234 95.5 17.9 769 92.9 14.9 764 -2.5* 13.1
Waist circumference
men cm 634 107.2 11.7 599 106.1 11.8 598 -1.1* 4.1
women cm 530 97.3 13.0 498 96.7 13.3 496 -0.7* 3.5
Triglycerides
mg/dL 1186 205.0 91.3 753 185.0 74.4 741 -19.1* 61.0
HDL Cholesterol
men mg/dL 635 46.9 17.4 395 47.6 13.3 384 1.1* 11.0
women mg/dL 526 51.3 16.6 338 53.2 15.6 331 2.3* 10.8
1 defined by the AHA/NHLBI 2004 [17]; 2 difference versus baseline; statistical test applied: t-test; * p < 0.0001. Adjusted for age.BMC Cardiovascular Disorders 2008, 8:30 http://www.biomedcentral.com/1471-2261/8/30
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sartan with 12.5 mg HCTZ resulted not only in a strong
reduction in blood pressure but also in a favourable
change in metabolic risk factors. These changes were more
pronounced in high cardiac risk patients like those with
metabolic syndrome or Diabetes mellitus compared to
patients with neither condition.
Blood pressure reduction
In the present study a blood pressure reduction of -27.2/-
13.4 mmHg was documented. Baseline blood pressure
values were comparable throughout the subgroups as was
the reduction in blood pressure induced by 16 mg cande-
sartan/12.5 mg HCT. In a previous study patients with
previously untreated severe hypertension (mean blood
pressure 178/117 mmHg) who received 16 mg cande-
sartan/12.5 mg HCTZ experienced a rapid blood pressure
reduction that peaked at -38/-29 mmHg [21]. The blood
pressure reduction in the present study matches well with
previous data and extends these by the finding that
patients previously uncontrolled will have a substantial
reduction in blood pressure when prescribed the fixed
dose combination. The absolute amount of blood pres-
sure lowering (in mmHg) appeared to be dependent on
baseline blood pressure but did not differ between patient
types (diabetes, metabolic syndrome and neither condi-
tion). Therefore patients with a higher blood pressure
value can expect a higher blood pressure lowering effect of
candesartan/HCTZ.
Reduction of cardiovascular risk factors
Throughout the study a reduction of cardiovascular risk
factors was observed. However one should consider the
short time frame (observational period 8 weeks) in which
the changes were observed and its relative magnitude (Fig-
ure 1). While a slight reduction of waist circumference
could be observed in all three patient groups, changes
were non-significant with respect to fasting blood glucose,
triglycerides and HDL cholesterol in patients that neither
had the metabolic syndrome nor diabetes (eumetabolic).
Patients with metabolic risk factors however showed a
pronounced response in these metabolic risk factors when
treated with candesartan/HCTZ. Previous studies includ-
ing the ALPINE (OR 0.12; 95%CI 0.01–0.97 vs. Thi-
azides) and the combined SCOPE and CHARM studies
(OR 0.80; 95%CI 0.67–0.95 vs. placebo) have already
demonstrated the reduced diabetes incidence in patients
taking candesartan [12,14,22]. In the randomized double
blind ALPINE study newly diagnosed hypertensive
patients on a low dose diuretic alone or in combination
with a betablocker were compared in their use of cande-
sartan without a calcium channel blocker and followed
for a year [14]. At a similar level of blood pressure reduc-
tion, patients on the candesartan fixed dose combination
had lower levels of plasma glucose, triglycerides and
higher HDL-cholesterol. At 12 months, 18 patients in the
hydrochlorothiazide group versus five in the candesartan
group had a 'metabolic syndrome', as defined by the
World Health Organization (P 0.007) despite 1 year of
active blood pressure-lowering therapy.
The underlying mechanism for the eumetabolic effects of
Candesartan are largely speculative. While there currently
is great attention to the PPARγ activating properties of
some ARBs [23] candesartan is less lipophilic [24] and
Table 3: Cardiovascular risk factors at baseline and follow-up in patients with Diabetes Mellitus1
Baseline 8 weeks Difference2
N m e a n±  S D N m e a n±  S D N m e a n±  S D
Blood pressure
systolic mmHg 1517 160.0 13.99 1489 134.1 11.2 1474 -25.9* 13.7
diastolic mmHg 1517 93.4 8.46 1489 81.2 6.7 1474 -12.2* 9.0
Fasting plasma glucose
mg/dL 1302 132.0 36.8 994 121.8 31.4 972 -10.8* 30.1
Waist circumference
men cm 633 109.4 12.8 601 108.2 12.2 597 -1.3* 2.5
women cm 570 100.6 14.7 530 99.5 13.6 526 -0.9* 2.7
Triglycerides
mg/dL 1187 205.1 104.5 834 185.6 78.4 811 -23.3* 76.2
HDL Cholesterol
men mg/dL 601 49.2 21.6 430 48.9 16.7 420 0.5** 14.36
women mg/dL 558 54.0 19.0 373 54.0 17.7 361 2.0** 14.79
1 diagnosis assigned by physician; 2 difference versus baseline; statistical test applied: t-test; * p < 0.0001; ** p < 0.05. Adjusted for age.BMC Cardiovascular Disorders 2008, 8:30 http://www.biomedcentral.com/1471-2261/8/30
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probably does not directly activate PPARγ. It has however
recently been reported that candesartan enhanced the
gene expression of PPARγ and induced the increased
expression of adipokines and a decrease in the pro-
inflammatory cytokine TNF-alpha [25]. On the leptin
contrary was reduced because of the repression of the Lep-
tin gene by activated PPARγ. Whether this is an adequate
explanation for the changes observed can only be specu-
lated at present.
Previous studies in primary care, similar in design as the
present study, have shown comparable results to the ones
reported here [26,27]. These studies were substantially
longer (6 and 9 month observations respectively) and
point towards the conclusion that the observed effects of
candesartan/HCTZ may well be even more pronounced
longer term. Differential effects of ARB treatment between
patients with and without the metabolic syndrome have
also been observed in the study by Kintscher et al. [26],
confirming the present result that severely metabolic
patients (diabetes > metabolic syndrome) will particularly
benefit from an ARB based combination treatment.
Risk for cardiovascular mortality (SCORE)
Cardiovascular risk scores have been developed to esti-
mate the cardiovascular risk of a given patient. They reflect
findings from epidemiological studies like Framingham
and PROCAM that a particular set of risk factors makes up
the largest proportion of risk. The SCORE method has
been developed under the auspices of the European Soci-
ety of Cardiology (ESC) and has been adapted to fit par-
ticular countries in Europe [18] and specific risk tables for
Relative change in the single risk factors and of the metabolic syndrome in total Figure 1
Relative change in the single risk factors and of the metabolic syndrome in total. The Metabolic syndrome is given, 
if 3 out of 5 criteria are met [17]. Significance: * P < 0.0001; ** P < 0.05; *** P = n.s.; Comparison between groups is a results 
of ANCOVA analysis (adjusted for age and gender); Differences vs. baseline are compared with a paired t-test (intraindividual 
comparison).
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Germany have been published [28]. 5% has been sug-
gested to be the intervention threshold for primary pre-
vention by a working group of the German Society of
Cardiology [29].
The documented baseline risk of in the present was well
beyond the intervention threshold of 5% disregarding
that most of these patients were eligible for intervention
based on a diagnosis of diabetes mellitus or concomitant
cardiovascular disease. Treating patients with the fixed
dose combination of 16 mg candesartan/12.5 mg HCTZ
resulted in a substantial risk reduction. Similar analyses
have been conducted in the primary care setting in a pre-
vious study. Bramlage et al. showed that Irbesartan treat-
ment (with or without HCTZ) led to a reduction of
cardiovascular risk in hypertensive type-2 diabetic
patients [30]. The effect was higher in men than in women
but no specific data were reported for different patient
subgroups. Also no effort was made to attribute SCORE
reductions to different risk factors making up the score.
Data from the present study point at an only partial
responsibility of the blood pressure lowering effect (-
27.2/-13.4 mmHg) but to the favourable metabolic
changes induced by candesartan. This was unexpected
given the dominant blood pressure lowering effect of the
drug and it is also welcome based on earlier data from the
Hypertension Optimal Treatment Study, that despite
good blood pressure control, the residing metabolic risk
factors were found to be an important cause of residual
risk [9]. Whether or not a candesartan based treatment
may narrow the gap between the cardiovascular risk of
naturally normal and well controlled patients is however
beyond the scope of the present study.
Limitations
The present results have to be considered against the back-
ground of potential limitations. The study was not con-
trolled and therefore the role of a placebo effect or the
withdrawal of antihypertensive agents is unknown. Sec-
ond, in the absence of a randomization procedure and not
consecutive inclusion the influence of unknown biases,
e.g. through patient selection, cannot be ruled out. Third,
changes in concomitant medication influencing the met-
abolic profile (lipid lowering agents, oral antidiabetic
agents or insulin) have not been documented in the
present study. Fourth, randomly high values for blood
pressure readings or metabolic changes may have resulted
in artificially large reductions consistent with the phe-
nomenon "regression to the mean", the extent of which is
difficult to determine. Among the strengths of the study
was the choice of the setting. Observational studies in pri-
mary care, which include typical patient groups and reflect
current treatment approaches, are useful for complement-
ing the findings of randomized controlled trials [31].
Conclusion
The present study confirms prior results from randomized
controlled trials that a candesartan 16 mg/HCTZ 12.5 mg
based treatment resulted in a good population blood
pressure control in actual practice. It further shows that
despite concerns about the metabolic effects of diuretics,
improvements in metabolic parameters may be seen in
patients who receive a low-dose diuretic with candesartan
as part of their overall medical care.
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